Placental growth factor as a target for the treatment of osteoporosis

US7357929B2 · kind B2 · utility

Assignees

• D. Collen Research Foundation VZW · BE
• K.U. Leuven Research & Development · BE
• VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW · BE

Inventors

• Peter Carmeliet · Blanden, BE
• Desire Collen · Winksele, BE
• Roger Bouillon · Herent, BE
• Gertrudis Carmeliet · Blanden, BE

Key dates

• Filing date: Jun 27, 2003
• Grant date: Apr 15, 2008
• Expiry date: Jun 27, 2023

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/34
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to antagonists of placental growth factor and signalling thereof, pharmaceutical compositions containing such antagonists and the use of such antagonists to prevent bone loss or bone mass and to enhance bone healing including the treatment of conditions which present with low bone mass and/or bone defects in vertebrates, and particularly mammals, including humans.